Cantitate/Preț
Produs

Critical Issues in Head and Neck Oncology: Key Concepts from the Seventh THNO Meeting

Editat de Jan B. Vermorken, Volker Budach, C. René Leemans, Jean-Pascal Machiels, Piero Nicolai, Brian O’Sullivan
en Limba Engleză Hardback – 3 iun 2021
This open access book discusses the most current issues in head and neck cancer with a focus on current trends such as biomarkers, precision medicine and immunotherapy. New approaches in the diagnosis such as liquid biopsies and imaging biomarkers to predict radiotherapy toxicity as well as approaches in the surgical management of head and neck cancers are discussed. The book discusses medical and surgical approaches in both primary, recurrent and metastatic disease and also covers approaches for rare head neck cancers.  
Readers will learn about the latest drug developments and epidemiological aspects in cancers ranging from Head and Neck Squamous Cell Cancer to Nasopharynx cancer.
Edited by a team of world leaders in Head and Neck Cancer, this volume serves as an easy reference to the head and neck oncology practitioner and provides a contemporary overview for specialists the field. The chapters are based on the latest data presented at the 7th Trends in Head and Neck Oncology Conference and reflect the most up-to-date information in the field.

Citește tot Restrânge

Preț: 40620 lei

Preț vechi: 42758 lei
-5% Nou

Puncte Express: 609

Preț estimativ în valută:
7774 8075$ 6457£

Carte disponibilă

Livrare economică 13-27 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783030632335
ISBN-10: 3030632334
Pagini: 373
Ilustrații: IX, 373 p. 39 illus., 33 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.77 kg
Ediția:1st ed. 2021
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland

Cuprins

Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC).- Promising biomarkers for early diagnosis and prognosis prediction in HNS.- Biomarkers to predict radiotherapy toxicity.- Biomarkers for hypoxia, HPVness and proliferation from imaging perspective.- Mechanism of cetuximab resistance and how to overcome it.- The role of liquid biopsy for monitoring disease evolution.- NK cells in immunotherapy: how important are they?.- Biomarkers for immune modulatory treatment in HNSCC.- Primary disease (1).- Novel approaches in surgical management of HNSCC.- The surgical approach to elderly patients with HNSCC .- The nonsurgical approach to locoregionally advanced HNSCC.- High-dose three-weekly or low-dose weekly cisplatin during radiation, what to prefer?.- Primary disease (2).- Where and when to use induction chemotherapy?.- Prognostic role of p16/HPV in non-oropharyngeal head and neck cancer.- Is there a role for neoadjuvant targeted and immunotherapies?.- Is there a role for adjuvant targeted and immunotherapies? .- Optimal supportive measures during primary treatment.- Precision Medicine in head and neck cancer: myth or reality.- Recurrent and / or metastatic disease.- Salvage surgery:  candidates, safe reconstruction, and results?.-  Re-irradiation for local relapses or second primaries: when and how?.- New promising targeted agents in first and second-line settings.- Update of immune therapies in recurrent/metastatic HNSCC.- Special Issue.- Patients with rare head neck cancers: do they need a different approach? .-Nasopharynx cancer.- New epidemiological aspects.- New developments in the management of nasopharyngeal carcinoma.- New drugs for recurrent/metastatic nasopharynx cancer.

Recenzii

“Each chapter is enhanced with coloured figures and diagrams and liberally supported by published references … . This publication is recommended to all clinicians involved in patient management with head and neck cancer as a ‘source of knowledge’ on the modern and future treatment options of this disease.” (PJ Bradley, The Journal of Laryngology & Otology, June 2, 2021)

Notă biografică

Prof. Jan B. Vermorken started his medical training in 1961, graduated in 1970 from the University of Amsterdam, the Netherlands, and became a board-certified specialist in internal medicine in 1975. Since that time he has worked in the field of Medical Oncology and was officially registered as a Medical Oncologist in the Netherlands in 1992. He received his PhD in Medical Sciences in 1986 from the Vrije Universiteit in Amsterdam. From May 1997 until October 1, 2009, he was appointed Professor of Oncology at the University of Antwerp (UA), and head of the Department of Medical Oncology at the University Hospital Antwerp (UZA), in Edegem, Belgium. After his retirement he remains connected to both University (Emeritus Professor) and University Hospital (consultant). His main fields of interest are head and neck oncology and gynecologic oncology. He chaired both the Head and Neck Cancer Group (2006-2009) and the Gynecologic Cancer Group (1983-1989) of the European Organization for the Research and Treatment of cancer (EORTC). He was founding chair of the Gynecologic Cancer InterGroup (GCIG: 1997-2003) and strongly involved in establishing the Head and Neck Cancer International Group (HNCIG) in 2015. He devotes a large part of his time to teaching, professional training, and continuing medical education.
Professor Vermorken is member of various scientific societies, member of several editorial boards of International journals, reviewer of multiple cancer journals and author or co-author of more than 700 publications. He was Editor-in-Chief of Annals of Oncology from 2009 to 2014 and is chief editor of the head and neck cancer section of The Oncologist (since 2003), and the head and neck section of Frontiers in Oncology (since 2015), is editorial chair of ONCOhemato (multidisciplinary journal; since 2007) in Belgium and chairs Oncotherapie (an internet platform) in The Netherlands (since 2007). He received the ESMO award in 2007 and on March 1, 2013 he received the title of Commander in the Order of Leopold for his contributions to oncology.
Jean-Pascal Machiels MD, PhD, is head of department of medical oncology and director of the Institut Roi Albert II Cancer centre, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels Belgium. He trained at Université Catholique de Louvain, Brussels, Belgium, where he gained his MD in 1993 and his PhD in 2001 and at Johns Hopkins School of Medicine, Baltimore USA, where he was a Fellow in Medical Oncology from 1998 until 2000,. His main interests include Head and Neck cancer, and phase 1 clinical trials. He has published more than two hundred papers reporting on clinical trials and translational research.
Prof. Volker Budach. MD is Head of the Depts. for Radiation Oncology at the Charité University Medicine Berlin. He became a board certified radiation oncologist at the University of Essen in 1985 and was appointedas full professor and chair of the Dept. for Radiation Oncology at the Charité University Clinics in 1993. He was board member and treasurer of the ESTRO during 1996 and 2004 and chairman of the EORTC-Radiooncology Group during 2000-2003, followed by the chairmanship o^ 330 peer reviewed publications cited in Pubmed

Professor C. René Leemans, MD, PhD is chair of the Department of Otolaryngology Head and Neck Surgery at the Amsterdam University Medical Centres, VUmc, Amsterdam. He is Director of the Advanced Fellowship Program in Head and Neck Surgery and Oncology at the VU University Medical Centre Amsterdam. His special interests include head and neck oncology, reconstructive and microvascular surgery, and basic research. René Leemans has made a sustained and internationally recognised contribution to cancer care and research in the field of head and neck oncology over the past decades. His scientific standing has been recognised by election as President of the Netherlands Society of Otolaryngology-Head and Neck Surgery, and the Dutch and European Head and Neck Societies. He also serves on the Leadership of the American Head and Neck Society (AHNS). He (co-)authored more than 400 papers and book chapters on head and neck oncology and is regularly invited to speak at international conferences and tutor at courses. He leads the successful Make Sense Awareness Campaign.
Professor O’Sullivan is the inaugural Bartley-Smith/Wharton Chair (Emeritus) in Radiation Oncology and immediate past Chair of the Head and Neck Program at the Princess Margaret Cancer Centre, University of Toronto. He is the Co-chair of the Head and Neck Steering committee of the US National Cancer Institute and Editor-in Chief of the UICC Manual of Clinical Oncology. He is Chair of the UICC Prognostic Factors Classification Committee, and Chair of the UICC Head and Neck Committee, co-editor of the UICC TNM Classification of Malignant Tumours and Liaison the AJCC Expert Committee on Head and Neck Cancer. He is also well recognized expert in the management of sarcoma and a past-President of the Connective Tissue Oncology Society (CTOS). He is one of three clinician members of the International Commission on Radiation Units (ICRU). Professor O’Sullivan has received multiple awards and honors for his work including, most recently, the 2020 American Society of Radiation Oncology (ASTRO) Gold Medal, the highest honor bestowed by the Society on revered members who have made outstanding contributions to the field of radiation oncology. This includes research, clinical care, teaching and service. He has lectured extensively throughout the world, and has published over 400 peer-review papers, more than 80 book chapters and edited more than 10 oncology textbooks.

Professor Piero Nicolai is Head of the Section of Otorhinolaryngology – Head and Neck Surgery, Department of Neurosciences, at the Azienda Ospedaliera of Padova Policlinico and Professsor of Otorhinolaryngology at the University of Padova. From 2006 to 2019 he has served as Professor and Chairman of the Unit of Otorhinolaryngology – Head and Neck Surgery at ASST Spedali Civili Brescia - University of Brescia. He received his MD degree at the University of Padova, where he completed his residency program in Otorhinolaryngology, and subsequently in Medical Oncology. His clinical and research activities are mainly focused on head and neck oncology and endoscopic sinus and skull base surgery. Prof. Nicolai has authored or co-authored 307 papers in peer-reviewed journals as well as 61 book chapters. He has been co-editor of 6 books, and Editor of 6 issues of Current Opinion in Otolaryngology & Head and Neck Surgery on Head and Neck Oncology. He is a member of the editorial board of the journals Annals of Otology, Rhinology & Laryngology, Head and Neck, International Journal of Head & Neck Surgery, The Laryngoscope, Clinical Otolaryngology, and Associate Editor of Frontiers in Oncology – Head and Neck Cancer Section.


Textul de pe ultima copertă

This open access book discusses the most current issues in head and neck cancer with a focus on current trends such as biomarkers, precision medicine and immunotherapy. New approaches in the diagnosis such as liquid biopsies and imaging biomarkers to predict radiotherapy toxicity as well as approaches in the surgical management of head and neck cancers are discussed. The book discusses medical and surgical approaches in both primary, recurrent and metastatic disease and also covers approaches for rare head neck cancers.  
Readers will learn about the latest drug developments and epidemiological aspects in cancers ranging from head and neck squamous cell cancer to nasopharynx cancer.
Edited by a team of world leaders in head and neck cancer, this volume serves as an easy reference to the head and neck oncology practitioner and provides a contemporary overview for specialists the field. The chapters are based on the latest data presented at the 7th Trends in Head and Neck Oncology Conference and reflect the most up-to-date information in the field.

Caracteristici

Brings into focus the latest advances in cancer precision medicine Discusses medical, radiological and surgical approaches to treatment Edited by key opinion leaders in the field This book is open access, which means that you have free and unlimited access